Soligenix announces agreement on the design of a second confirmatory placebo-controlled trial for hybryte™ with the european medicines agency

Randomized study with 18 weeks continuous treatment expected to replicate and extend results from the first, statistically significant phase 3 study princeton, n.j. , april 3, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received agreement from the european medicines agency (ema) on the key design components of a confirmatory phase 3 placebo-controlled study evaluating the safety and efficacy of hybryte™ (synthetic hypericin) in the treatment of cutaneous t-cell lymphoma (ctcl) patients with early-stage disease.
SNGX Ratings Summary
SNGX Quant Ranking